Why Moderna (MRNA) fell 19.51%
Moderna (MRNA) fell 19.51% on October 22, 2026 — Vaccine data leak hits Moderna before readout.
What happened
Moderna fell 19.5% after reports that data from its Phase 3 cancer vaccine trial leaked before the official readout, and the WSJ has since corroborated the leak.
Why it moved
Pre-readout data is the single biggest value driver for a company like Moderna, so an early leak that suggests an uncertain or weak result forces the market to reprice the vaccine's probability of success immediately.
Why it matters
Within Healthcare & Biotech, Moderna's oncology pipeline is one of the main tests of whether mRNA platforms can extend beyond infectious disease into cancer, so the sector narrative rides on this readout.
What would break the thesis
If the official Phase 3 data show strong efficacy and safety and the leaked numbers prove inaccurate, the drop could reverse sharply. Conversely, a confirmed weak result would validate the selloff.